New presentations of Viread launched and licence extended for use in younger patients

The nucleotide analogue tenofovir (Viread) has been licensed for use in young children with HIV infection and adolescents with hepatitis B.

Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY
Tenofovir diphosphate (the active metabolite of tenofovir disoproxil fumarate) inhibits HIV-1 reverse transcriptase and the HBV polymerase. | SCIENCE PHOTO LIBRARY

Viread can now be prescribed, in combination with other antiretrovirals, for children aged 2 years and older with HIV-1 infection. In addition, it may be used to treat chronic hepatitis B in adolescents aged 12 years and older with compensated liver disease, evidence of active viral replication, persistently elevated ALT levels and histological evidence of active inflammation and/or fibrosis.

New tablets and granules now available

In order to support dosing in children aged 6–12 years, Gilead has launched three new strengths of Viread tablets: 123mg (for children 17–22kg); 163mg (for children 22–28kg); and 204mg (for children 28–55kg). An oral granule formulation is also now available for children aged 2–6 years and for patients of all ages when a solid dosage form is not appropriate. The granules should be mixed with soft food (eg, yoghurt) before being taken.

Discontinue if renal dysfunction develops in children

Tenofovir is not recommended for use in children with renal impairment and should be discontinued in children who develop renal impairment.

View Viread drug records

Further information: Gilead Sciences

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Reversal of benefits after novel migraine prophylactics stopped, study shows

Reversal of benefits after novel migraine prophylactics stopped, study shows

Findings from a recent study indicate a return to pre-treatment...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...